Therefore, colon cancer progression and resistance to therapies may worsen, not only in the presence of chronic inflammatory diseases such as inflammatory bowel disease (IBD) [86], obesity [87] or hyperglycemia [51], but also by an inflammatory phenotype induced by genetic or epigenetic changes of HIPK2. This evidence concerns the gene HIPK2 and Hyperglycemia.